Barclays raised the firm’s price target on Edwards Lifesciences (EW) to $104 from $103 and keeps an Overweight rating on the shares. The firm updated the company’s estimates to reflect the cancellation of the JenaValve acquisition and management’s new 2026 outlook.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Stock (EW) Falls as FTC Wins Ruling to Block JenaValve Deal
- Edwards Lifesciences will not acquire JenaValve, updates FY26 guidance
- Edwards Lifesciences raises FY26 adjusted EPS view to $2.90-$3.05
- Edwards Lifesciences upgraded to Buy from Hold at TD Cowen
- Edwards Lifesciences price target raised to $108 from $104 at Goldman Sachs